Cargando…

Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022

Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres-Canchala, Laura, Cleves-Luna, Daniela, Arias-Valderrama, Oriana, Candelo, Estephania, Guerra, María Angelica, Pachajoa, Harry, Olaya, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856545/
https://www.ncbi.nlm.nih.gov/pubmed/36670605
http://dx.doi.org/10.3390/children10010054
_version_ 1784873657999294464
author Torres-Canchala, Laura
Cleves-Luna, Daniela
Arias-Valderrama, Oriana
Candelo, Estephania
Guerra, María Angelica
Pachajoa, Harry
Olaya, Manuela
author_facet Torres-Canchala, Laura
Cleves-Luna, Daniela
Arias-Valderrama, Oriana
Candelo, Estephania
Guerra, María Angelica
Pachajoa, Harry
Olaya, Manuela
author_sort Torres-Canchala, Laura
collection PubMed
description Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment. Methods: Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly. Results: Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them. Conclusion: SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations.
format Online
Article
Text
id pubmed-9856545
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98565452023-01-21 Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022 Torres-Canchala, Laura Cleves-Luna, Daniela Arias-Valderrama, Oriana Candelo, Estephania Guerra, María Angelica Pachajoa, Harry Olaya, Manuela Children (Basel) Review Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment. Methods: Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly. Results: Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them. Conclusion: SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations. MDPI 2022-12-26 /pmc/articles/PMC9856545/ /pubmed/36670605 http://dx.doi.org/10.3390/children10010054 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Torres-Canchala, Laura
Cleves-Luna, Daniela
Arias-Valderrama, Oriana
Candelo, Estephania
Guerra, María Angelica
Pachajoa, Harry
Olaya, Manuela
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
title Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
title_full Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
title_fullStr Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
title_full_unstemmed Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
title_short Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
title_sort systemic bevacizumab for recurrent respiratory papillomatosis: a scoping review from 2009 to 2022
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856545/
https://www.ncbi.nlm.nih.gov/pubmed/36670605
http://dx.doi.org/10.3390/children10010054
work_keys_str_mv AT torrescanchalalaura systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022
AT cleveslunadaniela systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022
AT ariasvalderramaoriana systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022
AT candeloestephania systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022
AT guerramariaangelica systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022
AT pachajoaharry systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022
AT olayamanuela systemicbevacizumabforrecurrentrespiratorypapillomatosisascopingreviewfrom2009to2022